The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here: https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

Thoas Fioretos

Thoas Fioretos

Research team manager

Thoas Fioretos

Chronic myeloid leukemia

Author

  • Thoas Fioretos

Editor

  • Sverre Heim
  • Felix Mitelman

Summary, in English

Chronic myeloid leukemia (CML) is a clonal bone marrow (BM) disease characterized by neoplastic overproduction of, mainly, granulocytes. The treatment of CML has changed dramatically with the introduction of tyrosine kinase inhibitors (TKIs) targeting the product of the underlying cytogenetic and molecular lesion in CML. The Philadelphia chromosome was the first consistent neoplasia-associated chromosomal abnormality reported; its discovery was a milestone in cancer cytogenetics. Treatment of CML has changed dramatically over the last decades. The chfromosome t(9;22) (q34;q11) or its variant translocations (seen in 5-10%) are detected in the great majority of BM cells from patients with CML.The introduction of imatinib and other TKIs has dramatically improved the clinical outcome for CML patients, and today, the vast majority of patients receiving TKI treatment in chronic phase (CP) remain in complete hematologic and cytogenetic remission with low to undetectable BCR-ABL1 fusion transcripts.

Department/s

  • Division of Clinical Genetics
  • BioCARE: Biomarkers in Cancer Medicine improving Health Care, Education and Innovation

Publishing year

2015

Language

English

Pages

153-174

Publication/Series

Cancer Cytogenetics : Chromosomal and Molecular Genetic Aberrations of Tumor Cells

Document type

Book chapter

Publisher

Wiley-Blackwell

Topic

  • Medical Genetics

Keywords

  • Cancer cytogenetics
  • Chronic myeloid leukemia
  • Philadelphia chromosome
  • Tyrosine kinase inhibitors

Status

Published

ISBN/ISSN/Other

  • ISBN: 9781118795569
  • ISBN: 9781118795538